Advertisement

May 6, 2019

Intact Vascular Launches the Tack Endovascular System in the United States

May 6, 2019—Intact Vascular, Inc. announced the first commercial use of its Tack endovascular system in multiple sites across the United States. This dissection repair device, which is implanted postangioplasty to resolve dissections in patients with peripheral artery disease (PAD), received FDA approval in April for above-the-knee (ATK) interventions.

The company noted that the Tack endovascular system is preloaded with six self-expanding nitinol implants for ATK interventions and can be deployed to treat multiple dissections using a single catheter, leaving behind > 70% less metal than stents.

In the company's announcement, Nicolas W. Shammas, MD, commented, “Dissections are an unavoidable consequence of balloon angioplasty. Now, with the Tack endovascular system, we have an effective minimal metal solution to treat dissections above the knee, further improving our angioplasty outcomes. I am extremely pleased with my experience using Tack implants and believe this device will facilitate better care for my PAD patients.” Dr. Shammas is Founder and Research Director of the Midwest Cardiovascular Research Foundation in Davenport, Iowa.

John Rundback, MD, added, “The Tack endovascular system brings us unique clinical and economic advantages in the office-based lab setting. With six implants preloaded into a single delivery system, physicians can quickly and easily provide precision dissection repair along the vessel length. This minimal metal therapy complements balloon angioplasty and avoids the complications a larger metal stent may cause, thereby preserving future treatment options.” Dr. Rundback is a vascular and interventional radiologist and Partner at the New Jersey Endovascular & Amputation Prevention Services, LLC in Teaneck, New Jersey.

Finally, Ehrin Armstrong, MD, stated, “In striving to provide the best care for patients, we actively seek new ways to improve the results of balloon angioplasty. Based on my clinical experience using the Tack endovascular system, I anticipate this targeted therapy will become standard of care for postangioplasty dissection repair.” Dr. Armstrong is an interventional cardiologist and Director of Interventional Cardiology at the Rocky Mountain Regional VA Medical Center in Denver, Colorado.

Advertisement


May 6, 2019

Boston Scientific's Vici Venous Stent Gains FDA Approval

May 6, 2019

Boston Scientific's Vici Venous Stent Gains FDA Approval